Enterprise AI in pharma is at a turning point. While adoption continues to accelerate, most organizations still struggle to move beyond pilots and into scalable, production-ready systems. The challenge is not the technology itself, but how it is applied across highly specialized, regulated workflows.
CapeStart’s Agent Factory approach introduces a new way to deploy AI in life sciences. Instead of relying on general-purpose models, it focuses on specialized, purpose-built agents designed for specific workflows, compliance requirements, and operational contexts.
This white paper explores how composable agent architectures can improve workflow accuracy, accelerate time to value, and enable scalable automation across clinical, regulatory, safety, and manufacturing functions. It also outlines a practical framework for moving from isolated AI experiments to enterprise-wide adoption.
Download the white paper to understand how specialized AI agents can transform complex pharma workflows into scalable, production-ready systems.
